Gapping up
In reaction to strong earnings/guidance:
- AMKR +16.6%, OMF +13.9%, MEDP +11.7%, VCRA +11.5%, HSTM +10.4%, FIX +8.2%, CVLT +7.4%, PII +7.2%, TNET +6.8%, AJRD +5.5%, IRDM +4.8%, IBTX +3.6%, IBTX +3.6%, PFE +3.4%, SHW +3.3%, MDC +3.2%, LXFR +2.7%, AGNC +2.7%, GLW +2.4%, OTIS +2.2%, RTX +2.1%, CMI +2.1%, LH +1.8%, MLM +1.8%, SPGI +1.7%, XRX +1.4%, JBT +1.2%, DHI +1.2%, HUN +0.9%, MO +0.8%, CR +0.7%, WAT +0.7%, FBC +0.6%
Other news:
- SPPI +49.4% (announces "positive" top-line results from ZENITH20 Phase 2 trial)
- LUMO +18.2% (to sell its Priority Review Voucher to Merck)
- BSM +12.3% (increases dividend)
- BLNK +6.1% (announces collaboration with EnerSys (ENS) to develop high-power wireless and enhanced DC fast charging systems)
- BNTX +4% (BNTX and PFE choose lead mRNA vaccine candidate, starts global Phase 2/3 study)
- CTSO +3.8% (REFRESH 2-AKI trial receives recommendation for study resumption from Data Monitoring Committee)
- PFE +3.5% (BNTX and PFE choose lead mRNA vaccine candidate, starts global Phase 2/3 study)
- CHMA +3.3% (announces data from CHIASMA OPTIMAL Phase 3 trial)
- ACIU +3.1% (reports new data for its next generation alpha-synuclein positron emission tomography-tracer during an oral presentation at the Alzheimer's Association International Conference)
- BHC +2.8% (Glenview (Larry Robbins) increases holding and discloses 5.9% active stake)
- TCRR +2.5% (commences public offering of 6 mln shares)
Analyst comments:
- SHOP +2.6% (upgraded to Buy from Neutral at Goldman)
- NET +2.2% (upgraded to Buy from Hold at Jefferies)
- CVNA +1.2% (initiated with an Overweight at Piper Sandler)
- SR +1% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ATHM +0.7% (upgraded to Outperform from Neutral at Credit Suisse)